Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis

Inflammation

Volumn 37, Issue 2, 2014, Pages 402-416

  Xiang, Xiao Song ^a   Li, Ning ^a   Zhao, Yun Zhao ^a   Li, Qiu Rong ^a   Li, Jie Shou ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

dendritic cell; endotoxemia; immune; mice

Indexed keywords

CD86 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERIAL TRANSLOCATION; CELL COUNT; CONTROLLED STUDY; DENDRITIC CELL; ENDOTOXEMIA; FEMALE; HOST RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SECONDARY INFECTION; SEPSIS; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD86; BACTERIAL TRANSLOCATION; CELLS, CULTURED; DENDRITIC CELLS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTOXEMIA; ESCHERICHIA COLI INFECTIONS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; SEPSIS; T-LYMPHOCYTES; THYMOSIN; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896327048     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9753-5     Document Type: Article

References (34)

1. Angus, D.C.; W.T. Linde-Zwirble, J. Lidicked, G. Clermont, J. Carcillo, and M.R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 29: 1303-1310.
2. Martin, G.S.; D.M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine 348: 1546-1554.
3. Levy, M.M.; R.P. Dellinger, S.R. Townsend, W.T. Linde-Zwirble, J.C. Marshall, J. Bion, C. Schorr, A. Artigas, G. Ramsay, R. Beale, M.M. Parker, H. Gerlach, K. Reinhart, E. Silva, M. Harvey, S. Regan, and D.C. Angus. 2010. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Medicine 36: 222-231.
4. The Lancet Infectious Diseases. For sepsis, the drugs don't work. Lancet Infect Dis 2012, 12:89.
5. Hotchkiss, R.S.; and I.E. Karl. 2003. The pathophysiology and treatment of sepsis. New England Journal of Medicine 348: 138-150.
6. Perl, M.; C.S. Chung, M. Garber, X. Huang, and A. Ayala. 2006. Contribution of anti-inflammatory/immune suppressive processes to the pathology of sepsis. Frontiers in Bioscience 11: 272-299.
7. Ayala, A.; C.S. Chung, P.S. Grutkoski, and G.Y. Song. 2003. Mechanisms of immune resolution. Critical Care Medicine 31: S558-S571.
8. Skrupky, L.P.; P.W. Kerby, and R.S. Hotchkiss. 2011. Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 115: 1349-1362.
9. Docke, W.D.; F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H.D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nature Medicine 3: 678-681.
10. Monneret, G.; F. Venet, B.J. Kullberg, and M.G. Netea. 2011. ICU-acquired immunosuppression and the risk for secondary fungal infections. Medical Mycology 49(Suppl 1): S17-S23.
11. Hotchkiss, R.S.; K.W. Tinsley, P.E. Swanson, R.E. Schmieg, J.J. Hui Jr.; K.C. Chang, D.F. Osborne, B.D. Freeman, J.P. Cobb, T.G. Buchman, and I.E. Karl. 2001. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. Journal of Immunology 166: 6952-6963.
12. Schefold, J.C.; D. Hasper, H.D. Volk, and P. Reinke. 2008. Sepsis: time has come to focus on the later stages. Medical Hypotheses 71: 203-208.
13. Banchereau, J.; and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
14. Lipscomb, M.F.; and B.J. Masten. 2002. Dendritic cells: immune regulators in health and disease. Physiological Reviews 82: 97-130.
15. Hotchkiss, R.S.; K.W. Tinsley, P.E. Swanson, M.H. Grayson, D.F. Osborne, T.H. Wagner, J.P. Cobb, C. Coopersmith, and I.E. Karl. 2002. Depletion of dendritic cells, but not macrophages, in patients with sepsis. Journal of Immunology 168: 2493-2500.
16. Guisset, O.; M.S. Dilhuydy, R. Thiébaut, J. Lefèvre, F. Camou, A. Sarrat, C. Gabinski, J.F. Moreau, and P. Blanco. 2007. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Medicine 33: 148-152.
17. Tinsley, K.W.; M.H. Grayson, P.E. Swanson, A.M. Drewry, K.C. Chang, I.E. Karl, and R.S. Hotchkiss. 2003. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. Journal of Immunology 171: 909-914.
18. Efron, P.A.; A. Martins, D. Minnich, K. Tinsley, R. Ungaro, F.R. Bahjat, R. Hotchkiss, M. Clare-Salzler, and L.L. Moldawer. 2004. Characterization of the systemic loss of dendritic cells in murine lymph nodes during polymicrobial sepsis. Journal of Immunology 173: 3035-3043.
19. Ding, Y.; C.S. Chung, S. Newton, Y. Chen, S. Carlton, J.E. Albina, and A. Ayala. 2004. Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice. Shock 22: 137-144.
20. Bohannon, J.; W. Cui, R. Cox, R. Przkora, E. Sherwood, and T. Toliver-Kinsky. 2008. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection. Journal of Immunology 180: 3038-3048.
21. Toliver-Kinsky, T.E.; W. Cui, E.D. Murphey, C. Lin, and E.R. Sherwood. 2005. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection. Journal of Immunology 174: 404-410.
22. Gautier, E.L.; T. Huby, F. Saint-Charles, B. Ouzilleau, M.J. Chapman, and P. Lesnik. 2008. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock. Journal of Immunology 180: 6941-6946.
23. Pène, F.; B. Zuber, E. Courtine, C. Rousseau, F. Ouaaz, J. Toubiana, A. Tazi, J.P. Mira, and J.D. Chiche. 2008. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. Journal of Immunology 181: 8513-8520.
24. Xiang, X.S.; Y.Z. Zhao, N. Li, Q.R. Li, and J.S. Li. 2010. Accumulation of DC in lamina propria induced by FMS-like tyrosine kinase 3 ligand aggravates the intestinal inflammatory response during endotoxemia. Inflammation 33: 34-45.
25. Samel, S.; M. Keese, M. Kleczka, S. Lanig, N. Gretz, M. Hafner, J. Sturm, and S. Post. 2002. Microscopy of bacterial translocation during small bowel obstruction and ischemina in vivo - a new animal model. BMC Surgery 2: 6-9.
26. Almansa, R.; J. Wain, E. Tamayo, D. Andaluz-Ojeda, I. Martin-Loeches, P. Ramirez, and J.F. Bermejo-Martin. 2013. Immunological monitoring to prevent and treat sepsis. Critical Care 25: 109-111.
27. Winter, C.; K. Taut, F. Länger, M. Mack, D.E. Briles, J.C. Paton, R. Maus, M. Srivastava, T. Welte, and U.A. Maus. 2007. FMS-like tyrosine kinase 3 ligand aggravates the lung inflammatory response to Streptococcus pneumoniae infection in mice: role of dendritic cells. Journal of Immunology 179: 3099-3108.
28. von Wulffen, W.; M. Steinmueller, S. Herold, L.M. Marsh, P. Bulau, W. Seeger, T. Welte, J. Lohmeyer, and U.A. Maus. 2007. Lung dendritic cells elicited by Fms-like tyrosine 3-kinase ligand amplify the lung inflammatory response to lipopolysaccharide. American Journal of Respiratory and Critical Care Medicine 176: 892-901.
29. Sun, C.M.; J.A. Hall, R.B. Blank, N. Bouladoux, M. Oukka, J.R. Mora, and Y. Belkaid. 2007. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. Journal of Experimental Medicine 204: 1775-1785.
30. Annane, D.; V. Sébille, C. Charpentier, P.E. Bollaert, B. François, J.M. Korach, G. Capellier, Y. Cohen, E. Azoulay, G. Troché, P. Chaumet-Riffaud, and E. Bellissant. 2001. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862-871.
31. Finfer, S. 2008. Corticosteroids in septic shock. New England Journal of Medicine 358: 188-190.
32. Goldstein, A.L.; A. Guha, M.M. Zatz, M.A. Hardy, and A. White. 1972. Purification and biological activity of thymosin, a hormone of the thymus gland. Proceedings of the National Academy of Sciences of the United States of America 69: 1800-1803.
33. Goldstein, A.L.; and A.L. Goldstein. 2009. From lab to bedside: emerging clinical applications of thymosin alpha1. Expert Opinion on Biological Therapy 9: 593-608.
34. Zhang, Y.; H. Chen, Y.M. Li, S.S. Zheng, Y.G. Chen, L.J. Li, L. Zhou, H.Y. Xie, and R.K. Praseedom. 2008. Thymosin alpha-1 and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. Journal of Infectious Diseases 198: 723-730.